Carbapenemases: the versatile beta-lactamases.
Queenan AM, Bush K.
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents. doi: 10.1128/CMR.00001-07.
Characterization of Enterobacter cloacae pneumonia: a single-center retrospective analysis.
Hennigs JK, Baumann HJ, Schmiedel S, Tennstedt P, Sobottka I, Bokemeyer C, Kluge S, Klose H.
Lung. 2011 Dec;189(6):475-83. doi: 10.1007/s00408-011-9323-2. Epub 2011 Oct 19.
Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, Xie L, Yang C, Ma X, Li H, Li W, Zhang X, Liao K, Man S, Wang S, Wen H, Li B, Guo Z, Tian J, Pei F, Liu L, Zhang L, Zou C, Hu T, Cai J, Yang H, Huang J, Jia X, Huang W, Cao B, Wang H.
Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01882-17. doi: 10.1128/AAC.01882-17. Print 2018 Feb.
In Vivo Pharmacodynamics of beta-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model.
Hagihara M, Kato H, Sugano T, Okade H, Sato N, Shibata Y, Sakanashi D, Hirai J, Asai N, Suematsu H, Yamagishi Y, Mikamo H.
Antibiotics (Basel). 2021 Sep 28;10(10):1179. doi: 10.3390/antibiotics10101179.
Infective endocarditis by Enterobacter cloacae: a systematic review and meta-analysis.
Ioannou P, Vamvoukaki R, Kofteridis DP.
J Chemother. 2022 Feb;34(1):1-8. doi: 10.1080/1120009X.2021.1959786. Epub 2021 Aug 9.
Case Report: Comprehensive Management of Pneumocystis Jiroveci Pneumonia (PJP) and Secondary Infections of Multiple-Drug Resistant Enterobacter cloacae complex and Pseudomonas aeruginosa in a Kidney Transplant Recipient with Sulfonamide Allergies.
Zhu L, Xu H, Pu Y, Fu C, Pan Q, Zhao H.
Infect Drug Resist. 2023 Sep 13;16:6185-6193. doi: 10.2147/IDR.S428890. eCollection 2023.
Production of 2,3-dihydroxyisovalerate by Enterobacter cloacae.
Yang Y, Zhang Z, Lu X, Gu J, Wang Y, Yao Y, Liao X, Shi J, Lye G, Baganz F, Hao J.
Enzyme Microb Technol. 2020 Oct;140:109650. doi: 10.1016/j.enzmictec.2020.109650. Epub 2020 Aug 12.
Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus.
Jing R, Yi QL, Zhuo C, Kang W, Yang QW, Yu YS, Zheng B, Li Y, Hu FP, Yang Y, Lin J, Zhang G, Zhang JJ, Wang T, Li J, Zhuo CY, Li X, Zhu YF, Xu YC.
J Antimicrob Chemother. 2024 Sep 3;79(9):2246-2250. doi: 10.1093/jac/dkae220.
Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
Rouse MS, Hein MM, Anguita-Alonso P, Steckelberg JM, Patel R.
Diagn Microbiol Infect Dis. 2006 Aug;55(4):333-6. doi: 10.1016/j.diagmicrobio.2006.01.029. Epub 2006 May 2.
Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
Mimoz O, Leotard S, Jacolot A, Padoin C, Louchahi K, Petitjean O, Nordmann P.
Antimicrob Agents Chemother. 2000 Apr;44(4):885-90. doi: 10.1128/AAC.44.4.885-890.2000.
